Drug Type Monoclonal antibody |
Synonyms Galcanezumab, Galcanezumab(Genetical Recombination), galcanezumab + [7] |
Target |
Mechanism CGRP antagonists(Calcitonin gene-related peptide antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (27 Sep 2018), |
RegulationFast Track (US), Breakthrough Therapy (US) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Galcanezumab-gnlm |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cluster Headache | US | 04 Jun 2019 | |
Migraine Disorders | US | 27 Sep 2018 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cluster Headache | Preclinical | IT | 22 May 2015 | |
Cluster Headache | Preclinical | ES | 22 May 2015 | |
Cluster Headache | Discovery | FR | 22 May 2015 | |
Cluster Headache | Discovery | BE | 22 May 2015 | |
Cluster Headache | Discovery | FI | 22 May 2015 | |
Cluster Headache | Discovery | DE | 22 May 2015 | |
Cluster Headache | Discovery | GR | 22 May 2015 | |
Cluster Headache | Discovery | DK | 22 May 2015 | |
Cluster Headache | Discovery | GB | 22 May 2015 | |
Cluster Headache | Discovery | NL | 22 May 2015 |
Phase 2 | 406 | galcanezumab 120mg (6-month treatment) | (rbrvvqokmt) = jqbnqwgfwl ajgreahkkd (nprofyigym, 4.64) View more | Positive | 01 Jun 2024 | ||
galcanezumab 240mg (6-month treatment) | (wrfbhyzzqa) = dqgcagtuoa rnztplkpdt (lveesuodnk ) | ||||||
Not Applicable | - | (wyumhpmfos) = No serious adverse events were noted in our cohort in the 6 months of anti-CGRP mAb use. The most common side effects being injection site pain/reactions (38/95) and constipation (35/95) tbrgqojazh (meghaivhrz ) | - | 25 Apr 2023 | |||
Phase 3 | 520 | (hzxswuvftm) = legokqqtmy flcbgkqfiq (mkjcwttmmp ) View more | Positive | 28 Jul 2022 | |||
Placebo | (hzxswuvftm) = ofhosyjcmr flcbgkqfiq (mkjcwttmmp ) View more | ||||||
Pubmed Manual | Not Applicable | 43 | safecizdga(fhbsmmcxpn) = eexleurudj lmvabgijqj (cfarwurhbp ) View more | Positive | 13 Jun 2022 | ||
NCT02797951 (Pubmed) Manual | Phase 3 | 164 | (ohlpxrgdqx) = ugtlsoohjj qrdhejhugi (ykgncsiiqe ) View more | Positive | 27 May 2022 | ||
Phase 3 | 1,022 | (stfxjkxhez) = Incidence of discontinuation from the OLE due to adverse events was 5%. ffzetlixgq (joorbbrjxq ) | Positive | 08 Apr 2022 | |||
Phase 4 | 65 | Erenumab (140 mg Erenumab SC) | uysdtbxlxu(dmzeedusef) = drkvifzuui dieohzzmmm (bcymfrvppo, xsmjqxhgda - kblcnenhys) View more | - | 22 Mar 2022 | ||
(240 mg Galcanezumab SC) | uysdtbxlxu(dmzeedusef) = xulsizraos dieohzzmmm (bcymfrvppo, ddaunvjwch - bynebtfdvg) View more | ||||||
Phase 3 | 165 | (bnayvaerdi) = qsnplsmmth jxgwnaqclx (qqppgoqjko, zyokqvlryl - daeknttdua) View more | - | 10 Feb 2022 | |||
Not Applicable | 156 | (xqlqhjkdzh) = kylosjfkki whpvjkvpls (lrdeljbegp ) | - | 26 Nov 2021 |